drugset / Trial / NCT01474135

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

NCT01474135

Phase 2 Completed 93 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a double-masked, randomized, controlled study assessing the safety and ocular hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to Travatan® Z in patients with elevated intraocular pressure

Timeline

Start
2011-12
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Travoprost Other / unclassified 0.004 %
Subject VEROSUDIL Small molecule 0.25 %
Subject VEROSUDIL Small molecule 0.5 %